BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/28/2024 4:34:28 AM | Browse: 188 | Download: 978
 |
Received |
|
2024-04-25 13:15 |
|
Peer-Review Started |
|
2024-04-25 13:15 |
|
First Decision by Editorial Office Director |
|
2024-08-18 05:38 |
|
Return for Revision |
|
2024-08-18 05:38 |
|
Revised |
|
2024-08-28 13:46 |
|
Publication Fee Transferred |
|
2024-09-15 16:08 |
|
Second Decision by Editor |
|
2024-09-14 02:40 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-09-14 07:04 |
|
Articles in Press |
|
2024-09-14 07:04 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-09-19 02:41 |
|
Publish the Manuscript Online |
|
2024-09-28 04:34 |
| ISSN |
1948-9366 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Clinical evaluation of sintilimab in conjunction with bevacizumab for advanced colorectal cancer with microsatellite stable-type after failure of first-line therapy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Liang Wang, Yong-Zhi Diao, Xin-Fu Ma, Yu-Shuang Luo, Qi-Jing Guo and Xiao-Qian Chen |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| 2021 Key Topic of the Qinghai Provincial Health System-Guiding Plan Topic |
No. 2021-WJZDX-43 |
|
| Corresponding Author |
Xiao-Qian Chen, Doctor, Attending Doctor, Department of Gastrointestinal Oncology Surgery, Affiliated Hospital of Qinghai University, No. 29 Tongren Road, West District, Xining 810000, Qinghai Province, China. cxq925@163.com |
| Key Words |
Immune checkpoint inhibitors; Bevacizumab; Colorectal cancer; Cytotoxic T lymphocytes; Tumor-associated macrophages; Cancer-associated fibroblasts |
| Core Tip |
In this study, immune checkpoint inhibitors (ICIs) in combination with bevacizumab were applied to microsatellite stable (MSS)/proficient mismatch repair (pMMR) colorectal cancer (CRC) patients with first-line treatment failure. It was found that ICIs combined with bevacizumab treatment significantly changed the tumor immune cells compared with the pre-treatment period. Additionally, ICIs combined with bevacizumab not only further improved their clinical efficacy compared with ordinary chemotherapy combined with anti-angiogenic drugs, but also yielded safe and controllable adverse drug reactions, which provided a new option for MSS/pMMR CRC patients experiencing 1st-line treatment failure. |
| Publish Date |
2024-09-28 04:34 |
| Citation |
Wang L, Diao YZ, Ma XF, Luo YS, Guo QJ, Chen XQ. Clinical evaluation of sintilimab in conjunction with bevacizumab for advanced colorectal cancer with microsatellite stable-type after failure of first-line therapy. World J Gastrointest Surg 2024; 16(10): 3277-3287 |
| URL |
https://www.wjgnet.com/1948-9366/full/v16/i10/3277.htm |
| DOI |
https://dx.doi.org/10.4240/wjgs.v16.i10.3277 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
